Savarese G, Benson L, Sundström J, et al. - Although outcomes in cardiorenal disease improves with administering renin–angiotensin–aldosterone system inhibitors (RAASi), there have been concerns regarding increased risk of incident hospitalization and death from coronavirus disease 2019 (COVID‐19). Researchers here examined how use of angiotensin‐converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs) or mineralocorticoid receptor antagonists (MRAs) associate with COVID‐19 hospitalization/death in a large nationwide population. From the Swedish National Patient Registry, they included a total of 1,387,746 patients with hypertension, heart failure, diabetes, kidney disease, or ischemic heart disease (60% receiving ACEi/ARB and 5.8% MRA) registered until February 1, 2020 and followed them until May 31, 2020. Of these patients, 7,146 (0.51%) had incident hospitalization/death from COVID‐19. Analysis suggested no correlation of using RAASi with raised risk of hospitalization for or death from COVID‐19.